# A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

> **NCT05227703** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 391 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Emraclidine 15 mg
- **DRUG:** Emraclidine 30 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05227703
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-09-11
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05227703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05227703, "A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05227703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*